Novartis AG
$150
−4.32% day
Novartis, the Basel-based drugmaker, as its shares trade in New York. Its earnings rest on a few patented medicines, so trial readouts and patent expiries move it more than the economy does.
Oct 23 · $149.52 · +4.8% vs the window’s open
the numbers23
| when | value | change |
|---|---|---|
| Sep 23 | $142.71 | |
| Sep 24 | $143.57 | +0.6% |
| Sep 25 | $145.46 | +1.3% |
| Sep 28 | $146.88 | +1.0% |
| Sep 29 | $145.71 | −0.8% |
| Sep 30 | $142.57 | −2.2% |
| Oct 1 | $141.05 | −1.1% |
| Oct 2 | $141.00 | 0.0% |
| Oct 5 | $140.93 | 0.0% |
| Oct 6low | $140.79 | −0.1% |
| Oct 7 | $143.28 | +1.8% |
| Oct 8 | $143.11 | −0.1% |
| Oct 9 | $143.75 | +0.4% |
| Oct 12 | $143.84 | +0.1% |
| Oct 13 | $142.41 | −1.0% |
| Oct 14 | $146.88 | +3.1% |
| Oct 15 | $150.38 | +2.4% |
| Oct 16 | $150.62 | +0.2% |
| Oct 19 | $150.20 | −0.3% |
| Oct 20 | $153.64 | +2.3% |
| Oct 21 | $153.93 | +0.2% |
| Oct 22high | $156.27 | +1.5% |
| Oct 23latest | $149.52 | −4.3% |
Lately
Novartis's pill remibrutinib cut multiple sclerosis relapses 35.2% and 31.2% against teriflunomide in pivotal trials, results that landed after the chart's last close. It trails Roche's rival BTK inhibitor on efficacy but has a better safety profile, and in the first new MS drug class in years a liver-safety edge can decide which one patients get.